ArticleLaryngoscope investigative otolaryngology2025
Nasal Septal Perforation and Hereditary Hemorrhagic Telangiectasia: Evolution in Management.
Article in Laryngoscope investigative otolaryngology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nasal Septal Perforation and Hereditary Hemorrhagic Telangiectasia: Evolution in Management.Laryngoscope investigative otolaryngology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To review septal perforation management and outcomes in patients with hereditary hemorrhagic telangiectasia (HHT). Methods: Collection and presentation of patient demographic, perforation size, and prior perforation and HHT treatment data over a 20-year period. Symptom and quality of life treatment outcomes were determined using the Nasal Obstruction Symptom Evaluation (NOSE)-Perf scale and the 5-Factor Glasgow Inventory (GBI-5F), respectively, in patients treated since 2017. Results: Nine patients met study criteria. Mean (range) age was 64.4 (52-80) years and seven were biological males. Mean (range) perforation length and height were 1.9 (1.2-2.6) and 1.4 (1.0-1.8) cm. Four patients were treated with a customized septal button, one with posterior septal resection, and four with endonasal bilateral mucosal flap repair supported with an interposition graft. The button prostheses were well tolerated and the surgical closures successful at 8-60 months postoperatively. Subjective responses in the first three patients, and NOSE-Perf with GBI-5F scores in the latter six patients, demonstrated symptom and quality of life improvement for all patients. Perforation repair patients demonstrated substantial improvement in mean GBI-5F subdomain scores for quality of life, self-confidence, and social involvement and all have undergone sodium tetradecyl sclerotherapy injection postoperatively without re-perforation. Conclusion: Symptom and quality of life improvement can be achieved in HHT patients with a perforation using customized septal buttons, posterior septal resection, or bilateral flap surgical repair. Surgical closure combined with injection sclerotherapy is feasible with a low risk of re-perforation and represents an effective treatment strategy in selected patients. Level of Evidence: 4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.